BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

PolyActiva Launches U.S. Trial of Glaucoma Implant Following Australia Success

PA5108, a new chemical entity, is an investigational, biodegradable ocular micro implant, designed to deliver sustained intraocular pressure control for ...

August 08, 2025 | News

Fapon Biopharma Enrolls First Patient in China Phase I Trial of Novel Immunotherapy FP008 for Solid Tumors

Fapon Biopharma, a biotech in developing therapeutic antibodies and fusion proteins, is delighted to announce the completion of the first patient enrollmen...

August 06, 2025 | News

iNtRON Bio Unveils World-First Dual-Action Engineered Phage Targeting Colorectal Cancer-Causing Bacteria

Successful validation of payloaded anti-colibactin toxin phage using IMPA™ technology • Demonstrated 'Dual-target Therapeut...

August 06, 2025 | News

Innovent Biologics gets FDA nod to begin Phase 1 trials of oral GLP-1R agonist IBI3032

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

August 05, 2025 | News

WuXi XDC’s New DP3 Facility Achieves GMP Release, Boosting Global Bioconjugate Manufacturing Capacity

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on t...

August 05, 2025 | News

Bridging Real-World Evidence and AI: Unlocking Smarter, Faster Clinical Research in Asia

Having worked with pharma clients, healthcare providers, and digital platforms across the Asia-Pacific region, I’ve seen the challenges first-hand&md...

August 04, 2025 | Opinion

Chipscreen Biosciences Receives FDA IND Approval for Brain-Penetrant Aurora B Inhibitor CS231295

Shenzhen Chipscreen Biosciences Co., Ltd. ("Chipscreen Biosciences") announced that its wholly owned subsidiary, Chipscreen Biosciences (USA) Ltd., has rec...

August 04, 2025 | News

Eflornithine Added to Australia’s PBS for Children with High-Risk Neuroblastoma

Eflornithine is now reimbursed by the government under Australia's Pharmaceutical Benefits Scheme (PBS). The Pharmaceutical Benefits Advisory C...

August 04, 2025 | News

Energenesis Completes Phase I Trial of ENERGI-F705PD, a Novel Oral Therapy for Parkinson’s Disease

The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pha...

August 04, 2025 | News

Luye Pharma Begins Phase 1 Trial of Novel Triple-Target Antidepressant LY03021 in China

Luye Pharma Group announced that the first subject has been enrolled in a Phase 1 clinical trial in China for its LY03021, which was filed ...

August 04, 2025 | News

Alphamab Oncology’s Bispecific ADC JSKN022 Clears IND Review in China

Alphamab Oncology announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug...

August 04, 2025 | News

South Korea’s DXVX Inks $220M Global Out-Licensing Deal for mRNA Cancer Vaccine with U.S. Biotech

Dx&Vx (DXVX) has signed its first-ever global out-licensing agreement since its establishment. DXVX announced that it has entered into a co-developmen...

July 31, 2025 | News

Alphamab Oncology’s HER2-Targeting ADC JSKN003 Secures FDA Orphan Drug Designation for Gastric and GEJ Cancers

Alphamab Oncology announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Orphan Drug Designation (ODD) by the U.S. Foo...

July 29, 2025 | News

Bristol Myers Squibb and Bain Capital Launch New Biotech Company with $300M to Advance Autoimmune Therapies

Five immunology assets in-licensed from BMS with potential to address unmet needs for patients with autoimmune diseases, including late-stage asset for...

July 29, 2025 | News

Stay Connected